![Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications | Abdominal Radiology Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications | Abdominal Radiology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00261-024-04188-w/MediaObjects/261_2024_4188_Figa_HTML.png)
Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications | Abdominal Radiology
![Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer | Business Wire Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer | Business Wire](https://mms.businesswire.com/media/20210527005291/en/840088/22/Lantheus%C2%AE_Holdings_370px.jpg)
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer | Business Wire
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA
![Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial) - Curium Pharma Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial) - Curium Pharma](https://www.curiumpharma.com/wp-content/uploads/2018/05/Curium-wall.jpg)
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial) - Curium Pharma
![Frontiers | Comparative study of 18F-DCFPyL PET/CT and 99mTc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer Frontiers | Comparative study of 18F-DCFPyL PET/CT and 99mTc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer](https://www.frontiersin.org/files/Articles/1201977/fmed-10-1201977-HTML-r1/image_m/fmed-10-1201977-t001.jpg)
Frontiers | Comparative study of 18F-DCFPyL PET/CT and 99mTc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer
![Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications | Abdominal Radiology Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications | Abdominal Radiology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00261-024-04188-w/MediaObjects/261_2024_4188_Fig1_HTML.jpg)
Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications | Abdominal Radiology
![Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer | Lantheus Holdings, Inc. Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer | Lantheus Holdings, Inc.](https://investor.lantheus.com/sites/g/files/knoqqb75041/themes/site/nir_pid246/dist/images/logo.png)